Raptor Pharmaceutical Inc. (RPTP) Announces Management Changes

NOVATO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Ashley Gould, J.D. as its Senior Vice President, General Counsel and Corporate Governance. In addition, Ted Daley, Chief Business Officer, will be leaving the company at the end of September to pursue other interests.

"I am delighted to welcome Ashley to Raptor's executive team," said Julie Anne Smith, President and CEO of Raptor Pharmaceutical. "She has highly relevant expertise in biopharma spanning regulatory, quality assurance, governmental, and legal in addition to other functions. As Raptor continues to grow, I am confident she will prove an excellent strategic addition and I look forward to her counsel. Separately, I would like to thank Ted for all of the contributions he has made to Raptor's success over the years. His involvement across all functions has been invaluable as we've grown into a commercial, global organization. On behalf of the Board and other members of the executive team, we wish him well in his future endeavors."

Most recently Ms. Gould served as Senior Vice President, Governmental Affairs and Chief Legal and Compliance Officer for Hyperion Therapeutics. Before that, she held a number of positions of increasing responsibility at 23andMe, culminating in her appointment as Vice President, Corporate Development and Chief Legal Officer. Previously she was Vice President, Legal Affairs at CoTherix, where she worked on the company's acquisition by Actelion, and an associate at the law firms of O'Melveny & Myers and Wilson Sonsini Goodrich & Rosati. Ms. Gould received a B.S. in Political Economy of Natural Resources from University of California, Berkeley and a J.D. from the University of San Francisco School of Law.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.

CONTACT: COMPANY CONTACT: Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications Raptor Pharmaceutical Corp. (415) 408-6351 INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 [email protected] MEDIA CONTACT: Cammy Duong Canale Communications (619) 849-5382 [email protected]

Suggested Articles

The top dose of Regeneron's COVID-19 antibody lowered virus levels and relieved symptoms more quickly than placebo in non-hospitalized patients.

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.